U.S. and UK to eliminate drug tariffs, boost NHS payments, and improve market access.

The U.S. and U.K. are set to eliminate tariffs on pharmaceuticals, medical technology, and ingredients, with the UK agreeing to raise NHS payments for new medicines by 25% and revise its cost-effectiveness evaluation threshold. The deal, expected at the White House, aims to boost investment in the UK’s pharmaceutical sector, address concerns over stalled projects by companies like AstraZeneca and Merck, and align pricing with other wealthy nations. The UK will also reduce rebates on branded drugs and increase spending on medicines, while U.S. drug exports to the UK will gain tariff-free access. The agreement follows months of negotiations and pressure from the U.S. to improve market access and pricing fairness.